{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:21:54Z","timestamp":1793362914130,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"\n Background:<\/jats:title>\n Dried blood spots (DBSs) are promising candidates for therapeutic drug monitoring. In this study, a simple method for the simultaneous measurement of tyrosine kinase inhibitors (TKIs), including bosutinib, dasatinib, ibrutinib, imatinib, nilotinib, and ponatinib, using DBS was developed and validated. The prediction of the plasma concentration of TKIs based on the TKI concentrations in the DBS was assessed using the developed measurement method.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n DBS was prepared using venous blood on Whatman 903 cards. One whole DBS sample containing the equivalent of 40 \u03bcL of blood was used for the analysis. The analytical method was validated according to the relevant guidelines. For clinical validation, 96 clinical samples were analyzed. The regression equation was derived from a weighted Deming regression analysis, and correction factors for calculating the estimated plasma concentrations (EPCs) of the analytes from their concentrations in the DBS and the predictive performance of EPC were evaluated using 2 conversion equations.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n This method was successfully validated. Hematocrit had no significant effect on the method's accuracy or precision. Ibrutinib was stable in the DBS for up to 8 weeks at room temperature, whereas all BCR-ABL TKIs were stable for 12 weeks. All BCR-ABL TKIs exhibited similar predictive performance for EPCs using both calculation methods. Good agreement between EPCs and the measured plasma concentrations of bosutinib, imatinib, and ponatinib was observed with both conversion equations. However, Bland\u2013Altman analysis showed that blood sampling time affected the EPC accuracy for dasatinib and nilotinib.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n A simple method for the simultaneous determination of BCR-ABL and Bruton TKI concentrations in DBS was developed and validated. Owing to the small clinical sample size, further clinical validation is needed to determine the predictive performance of EPCs for the 6 TKIs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000997","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T14:03:02Z","timestamp":1655215382000},"page":"762-770","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-0418","authenticated-orcid":false,"given":"Yuji","family":"Mukai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Hokkaido, Japan;"},{"name":"Department of Pharmacy, University of Tsukuba Hospital, Ibaraki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunari","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Biotage Japan Ltd., Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Blood Disorders Center, Aiiku Hospital, Hokkaido, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Hokkaido, Japan;"},{"name":"Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Inotsume","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Hokkaido, Japan;"},{"name":"Division of Practical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5319-5065","authenticated-orcid":false,"given":"Takaki","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Hokkaido, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0000000000000654","article-title":"Therapeutic drug monitoring of oral anticancer drugs: the Dutch pharmacology oncology group-therapeutic drug monitoring protocol for a prospective study","volume":"41","author":"Groenland","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40164-018-0101-1","article-title":"Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia","volume":"7","author":"Mita","year":"2018","journal-title":"Exp Hematol Oncol."},{"key":"R5-20250603","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-8722-5-23","article-title":"Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation","volume":"5","author":"Takahashi","year":"2012","journal-title":"J Hematol Oncol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clml.2018.10.005","article-title":"Ibrutinib dose adherence and therapeutic efficacy in non-Hodgkin lymphoma: a single-center experience","volume":"19","author":"Williams","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e56813","DOI":"10.1371\/journal.pone.0056813","article-title":"Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice","volume":"8","author":"Santoleri","year":"2013","journal-title":"PLoS One"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12032-017-0958-6","article-title":"Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors","volume":"34","author":"Rychter","year":"2017","journal-title":"Med Oncol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","article-title":"Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry","volume":"903","author":"Kralj","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4155\/bio.15.101","article-title":"DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application","volume":"7","author":"Antunes","year":"2015","journal-title":"Bioanalysis"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/jphp.12757","article-title":"Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling","volume":"69","author":"Boons","year":"2017","journal-title":"J Pharm Pharmacol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"e0225225","DOI":"10.1371\/journal.pone.0225225","article-title":"Development and validation of LC-MS\/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients","volume":"14","author":"Iacuzzi","year":"2019","journal-title":"PLoS One"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"114418","DOI":"10.1016\/j.jpba.2021.114418","article-title":"Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors","volume":"207","author":"Verougstraete","year":"2021","journal-title":"J Pharm Biomed Anal."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"Li","year":"2010","journal-title":"Biomed Chromatogr."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.4155\/bio.15.63","article-title":"The performance of five different dried blood spot cards for the analysis of six immunosuppressants","volume":"7","author":"Koster","year":"2015","journal-title":"Bioanalysis"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"121928","DOI":"10.1016\/j.jchromb.2019.121928","article-title":"Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma","volume":"1137","author":"Mukai","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/FTD.0000000000000825","article-title":"Simultaneous quantification of BCR-ABL and Bruton tyrosine kinase inhibitors in dried plasma spots and its application to clinical sample analysis","volume":"43","author":"Mukai","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4155\/bio.14.298","article-title":"What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?","volume":"7","author":"Koster","year":"2015","journal-title":"Bioanalysis"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"122140","DOI":"10.1016\/j.talanta.2021.122140","article-title":"Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS\/MS method","volume":"226","author":"Verougstraete","year":"2021","journal-title":"Talanta"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0000000000000653","article-title":"Interior temperature and relative humidity of an envelope during mail transport by the Japan Post in the Summer: preliminary study for a stability test of dried blood spot samples sent as regular mail","volume":"41","author":"Mukai","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/clinchem\/44.5.1024","article-title":"Performance of Deming regression analysis in case of misspecified analytical error ratio in method comparison studies","volume":"44","author":"Linnet","year":"1998","journal-title":"Clin Chem."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"122466","DOI":"10.1016\/j.jchromb.2020.122466","article-title":"Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites","volume":"1162","author":"Retmana","year":"2021","journal-title":"J Chromatogr B"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","article-title":"Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS\/MS methods","volume":"31","author":"Miura","year":"2016","journal-title":"Drug Metab Pharmacokinet."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:08:38Z","timestamp":1748956118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000997","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"2022-02-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}